Company record
Breckenridge Pharmaceutical, Inc.
0 FDA warning letters since 2023 and 5 recalls in the last 12 months.
Get an email the day FDA posts anything new about Breckenridge Pharmaceutical, Inc..
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Jun 17 | Class II | Breckenridge Pharmaceutical, Inc. Drug |
Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by… CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |
| Jun 17 | Class II | Breckenridge Pharmaceutical, Inc. Drug |
Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berke… CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |
| May 13 | Class II | Breckenridge Pharmaceutical, Inc. Drug |
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, … CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit |
| Dec 10, 2025 | Class II | Breckenridge Pharmaceutical, Inc. Drug |
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkel… CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit |
| Dec 10, 2025 | Class II | Breckenridge Pharmaceutical, Inc. Drug |
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC… CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit |